The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CTK8E6839     [[(2R)-1-(6-aminopurin-9- yl)propan-2...

Synonyms: Tox21_113627_1, 202138-50-9, NCGC00183876-03, Tenofovir Disoproxil Fumarate
This record was replaced with 5481350.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tenofovir Disoproxil Fumarate

  • BACKGROUND: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors (NRTIs) with once-daily dosing approved for use in HIV-1 infection [1].
  • This study evaluated the anti-HBV activity of TDF compared to ADV in HIV/HBV-coinfected subjects [2].
  • There was no difference in toxicity between the 2 treatment arms, with 11 subjects (5 ADV and 6 TDF) experiencing elevations of serum ALT on treatment [2].

Psychiatry related information on Tenofovir Disoproxil Fumarate


High impact information on Tenofovir Disoproxil Fumarate


Analytical, diagnostic and therapeutic context of Tenofovir Disoproxil Fumarate

  • Forty-four asymptomatic HIV patients with undetectable viral load receiving a ddI-based HAART were recruited and switched to ddI plus TDF (ddI + TDF) and nevirapine (n = 22) or maintained with the same baseline ddIbased HAART scheme (n = 22) [4].


  1. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda, K., Vela, J.E., Myrick, F., Ray, A.S., Miller, M.D. Antivir. Ther. (Lond.) (2006) [Pubmed]
  2. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Peters, M.G., Andersen, J., Lynch, P., Liu, T., Alston-Smith, B., Brosgart, C.L., Jacobson, J.M., Johnson, V.A., Pollard, R.B., Rooney, J.F., Sherman, K.E., Swindells, S., Polsky, B. Hepatology (2006) [Pubmed]
  3. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. Karrer, U., Ledergerber, B., Furrer, H., Elzi, L., Battegay, M., Cavassini, M., Gayet-Ageron, A., Hirschel, B., Schmid, P., Russotti, M., Weber, R., Speck, R.F. AIDS (2005) [Pubmed]
  4. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. López, S., Negredo, E., Garrabou, G., Puig, J., Ruiz, L., Sanjurjo, E., Ramos, X., Infante, A.B., Casademont, J., Cardellach, F., Clotet, B., Miró, O. AIDS Res. Hum. Retroviruses (2006) [Pubmed]
WikiGenes - Universities